Vimarsana.com

Latest Breaking News On - First turn management - Page 1 : vimarsana.com

Parkman Healthcare Partners LLC Takes $4.41 Million Position in Nuvalent, Inc. (NASDAQ:NUVL)

Parkman Healthcare Partners LLC acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,867 shares of the company’s stock, valued at approximately $4,406,000. Parkman Healthcare Partners LLC owned about 0.10% of […]

Deborah-ann-miller
Robertw-baird
Nuvalent-inc
Jefferies-financial-group
Affinity-asset-advisors
Charles-schwab-investment-management-inc
Parkman-healthcare-partners
Securities-exchange-commission
First-turn-management
Nasdaq
Free-report
Healthcare-partners

Avoro Capital Advisors LLC Increases Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,755,555 shares of the biotechnology company’s stock after buying an additional 85,555 shares during the quarter. Ascendis Pharma A/S […]

Massachusetts
United-states
Ascendis-pharma
Massachusetts-financial-services-co
Westfield-capital-management-co
First-turn-management
Avoro-capital-advisors
Jpmorgan-chase-co
Morgan-stanley
Wells-fargo-company
Cantor-fitzgerald
Free-report

Bellevue Group AG Has $16.70 Million Holdings in Verona Pharma plc (NASDAQ:VRNA)

Bellevue Group AG decreased its position in Verona Pharma plc (NASDAQ:VRNA – Free Report) by 1.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 839,996 shares of the company’s stock after selling 16,362 shares during the period. Bellevue Group AG owned about 1.05% of Verona Pharma […]

United-states
American
Verona-pharma
Piper-sandler
Kathleena-rickard
American-century-companies-inc
Hermes-inc
Clearbridge-investments
Eventide-asset-management
Nasdaq
Bellevue-group
First-turn-management

Seven Eight Capital LP Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Seven Eight Capital LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,636 shares of the biotechnology company’s stock, valued at approximately $2,347,000. A number of […]

Massachusetts
United-states
Stifel-nicolaus
Ascendis-pharma
Westfield-capital-management-co
Exchange-commission
First-turn-management
Ascendis-pharmaas-company-profile
Morgan-stanley
Wells-fargo-company
Massachusetts-financial-services-co
Jpmorgan-chase-co

Rhenman & Partners Asset Management AB Has $12.52 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Rhenman & Partners Asset Management AB lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,912 shares of the biopharmaceutical company’s stock after selling 50,088 shares during the quarter. Rhenman & Partners Asset […]

Fady-ibraham-malik
Robert-wong
Raymond-james
Barclays
Cytokinetics-incorporated
Needham-company
First-turn-management
Charles-schwab-investment-management-inc
Norges-bank
Vanguard-group-inc
Securities-exchange-commission

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,275 shares of the biopharmaceutical company’s stock after purchasing an additional 16,353 shares during the quarter. Rafferty Asset Management LLC’s […]

Johnt-henderson
Fady-ibraham-malik
Cytokinetics-company-profile
Norges-bank
Needham-company
Barclays
Vanguard-group-inc
Charles-schwab-investment-management-inc
Rafferty-asset-management
First-turn-management
Cytokinetics-incorporated

Immunocore Holdings plc (NASDAQ:IMCR) Receives $81.85 Consensus Target Price from Analysts

Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) has received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year […]

Wellington
New-zealand-general
New-zealand
Bellevue-group
First-turn-management
Immunocore-holdings
Jpmorgan-chase-co
Canaccord-genuity-group
Polar-capital-holdings-plc
Nasdaq
Wellington-management-group

4,500 Shares in Nuvalent, Inc. (NASDAQ:NUVL) Purchased by Harvest Investment Services LLC

Harvest Investment Services LLC bought a new stake in Nuvalent, Inc. (NASDAQ:NUVL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,500 shares of the company’s stock, valued at approximately $331,000. A number of other hedge funds also recently added to or […]

Alger
Algeria
Matthew-shair
Leerink-partnrs
Fred-alger-management
Jefferies-financial-group
Harvest-investment-services
Nasdaq
Nuvalent-inc
Jpmorgan-chase-co
First-turn-management
Securities-exchange-commission

Disc Medicine's (IRON) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $85.00 target price on the stock. IRON has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $43.00 price […]

United-states
Raymond-james
William-richard-white
Stifel-nicolaus
Jennison-associates
Disc-medicine-company-profile
Victory-capital-management-inc
Cantor-fitzgerald
Pricet-rowe-associates-inc
Nasdaq
Disc-medicine-inc
First-turn-management

Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from Analysts

Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective […]

Wellington
New-zealand-general
New-zealand
Wellington-management-group
Polar-capital-holdings-plc
Nasdaq
First-turn-management
Immunocore-company-profile
Needham-company
Immunocore-holdings
Jpmorgan-chase-co

vimarsana © 2020. All Rights Reserved.